Short-stay units for low-risk acute HF could reduce cost, improve quality of life

A short-stay strategy designed to lower cost of care may improve quality of life of low-risk patients with acute HF in the ED, but the trial was underpowered due to low enrollment during the COVID-19 pandemic, researchers reported.
The results of the multicenter randomized SSU-AHF trial were published in JAMA Network Open.
“The cost of heart failure is projected to increase from $3.7 billion in 2012 to $69.8 billion in 2030, with hospitalization for acute HF being the greatest contributor. Hospitalization is also a marker for serious adverse events,” Peter S. Pang, MD, MS, chair of

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart